Bhagirathbhai Dholaria, MBBS, on Administering Axi-Cel in the Outpatient Setting for LBCL


The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings.

“Our analysis showed that yes, with appropriate safety guards and training and infrastructure, CAR T cell therapy, especially axi-cel, which has highest risk of cytokine release syndrome and neurotoxicity compared to other CD19-directed CAR T cell therapies such as tisa-cel and liso-cel, it can be still safely given.”

Clinicians from University of Vanderbilt investigated outcomes with remote monitoring patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel; Yescarta) and found that safety and efficacy outcomes were similar between patients treated in inpatient and outpatient settings. Data from the retrospective analysis were presented at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke with coauthor Bhagirathbhai Dholaria, MBBS, assistant professor of medicine at Vanderbilt University Medical Center, to learn more about the study and the favorable outcomes observed in patients treated in the outpatient setting. He discussed the advantages for both patients and hospitals with outpatient chimeric antigen receptor (CAR) T-cell therapy treatments.

For more coverage of the 2023 Tandem Meetings, click here.

Akosile TA, Dholaria B, Baer B, et al. The impact of telemedicine and wearable devices in improving the safety profile of outpatient chimeric antigen receptor T-Cell (CAR-T) therapies: A case-control study. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida. Abstract #201
Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.